Family program (MILAP) to reduce depression and partner violence for young married women in Nepal

A Randomized Controlled Trial of a Multi-component Family Intervention to Lower Depression and Address Intimate Partner Violence (MILAP) Among Young Women in Nepal

NA · Possible · NCT06834867

This project will test whether the MILAP family-based program can lower depression and PTSD symptoms and reduce intimate partner violence for married women aged 15–24 who live with their husbands and mothers-in-law in Nepal.

Quick facts

PhaseNA
Study typeInterventional
Enrollment900 (estimated)
Ages15 Years to 24 Years
SexAll
SponsorPossible (other)
Locations1 site (Kathmandu, Bagmati)
Trial IDNCT06834867 on ClinicalTrials.gov

What this trial studies

This interventional program delivers a multi-component family intervention (MILAP) to households where young married women report recent intimate partner violence, involving the wife, her husband, and her mother-in-law. The program combines family-level sessions with mental health components adapted for the local context and is delivered in Maithili or Nepali. Eligible households are enrolled in the Kathmandu/Bagmati catchment area and outcomes including depressive and PTSD symptoms and ongoing IPV are measured over time. Participants with severe medical/psychological contraindications (for example recent hospitalization for IPV or severe cognitive impairment) are excluded and referred for appropriate care.

Who should consider this trial

Good fit: Ideal candidates are married women aged 15–24 who report physical, sexual, or controlling intimate partner violence in the past year, live with their husband and mother-in-law, speak Maithili or Nepali, and plan to remain in the household during the study.

Not a fit: People unlikely to benefit include pregnant women, those with recent IPV severe enough to require hospitalization, individuals with significant cognitive impairment, or anyone with severe alcohol dependence (SADQ > 31), who are excluded or diverted to other services.

Why it matters

Potential benefit: If successful, the MILAP approach could reduce depression and trauma symptoms and decrease ongoing partner violence by improving family dynamics and support.

How similar studies have performed: Some CBT-based programs have improved depression after women left abusive relationships, but multi-generational family interventions for women still living with abusive partners in low-resource settings remain largely untested.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Married women aged 15-24 years, their husbands and MILs sharing a household;
* Living in the catchment area with no stated intention of leaving during the study period;
* Participants speaking in Maithili or Nepali;
* Wife reporting Intimate Partner Violence (physical, sexual or abusive control) in last 12 months as measured by three questions from the International Violence Against Women Survey (IVAWS);
* Expressing desire to remain in the current relationship/family

Exclusion Criteria:

* Pregnant women;
* History of IPV severe enough to result in hospitalization in the past 12 months;
* Significant cognitive problems/disability precluding participation;
* Any participant with Severe Alcohol Dependence, defined as Severity of Alcohol Dependence Questionnaire (SADQ) \> 31 (those with mild to moderate dependance will be referred but not excluded)

Where this trial is running

Kathmandu, Bagmati

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Intimate Partner Violence, Depression, PTSD - Post Traumatic Stress Disorder, Family Intervention, Mental Health, Nepal, MILAP

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.